Epigenetic drug discovery and tools
 

Discovery Network

CellCentric has established a hub & spoke network of scientific excellence across different but overlapping areas of research within epigenetics, including chromatin modifying enzymes, cancer initiation models, pluripotency and embryogenesis.  The Discovery Network comprises over 30 of the key epigenetics Principal Investigators (PIs) and their laboratories, from leading institutions around the world.
 
Together these PIs have published more than 110 articles in Nature, Science and Cell and over 1000 in the leading journals covering epigenetics. This record is unmatched by any other company in the epigenetics space and helps CellCentric identify and effectively prioritise epigenetic drug targets and supporting technologies.
 
The Discovery Network is based on equitable agreements and relationships that have been built over a number of years. CellCentric does not publicise directly who is in the Network but Technology Transfer Offices of Institutions with which the company interacts include: 

 
 
The Network meets the needs of multiple stakeholders (PIs, Technology Transfer Offices, Institute leaders and research funders). CellCentric assesses pre-publication proprietary insights to identify innovations of commercial interest, opportunities that are truly competitive and ahead of the game.  In return the PIs gain an objective view on the commercial application of new ideas and a corporate partner in CellCentric with whom they can seed drug discovery programmes whilst not upsetting the existing dynamic of their laboratory.  Technology Transfer Offices also benefit from having an organisation that works with them to provide depth and breadth of knowledge that they would otherwise lack in the epigenetic space.